Welcome to LookChem.com Sign In|Join Free

CAS

  • or

25014-27-1

Post Buying Request

25014-27-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

25014-27-1 Usage

Description

POLY-GAMMA-BENZYL L-GLUTAMATE is a macromolecule composed of repeating gamma-benzyl-L-glutamyl units. It is soluble in CHCl3 and has unique chemical properties that make it suitable for various applications across different industries.

Uses

Used in Pharmaceutical Industry:
POLY-GAMMA-BENZYL L-GLUTAMATE is used as a pharmaceutical compound for its potential therapeutic applications. Its unique structure and chemical properties allow it to interact with various biological systems, making it a promising candidate for the development of new drugs and therapies.
Used in Cosmetics Industry:
In the cosmetics industry, POLY-GAMMA-BENZYL L-GLUTAMATE is used as an ingredient in skincare and beauty products due to its ability to enhance skin hydration and improve the overall appearance of the skin.
Used in Research and Development:
POLY-GAMMA-BENZYL L-GLUTAMATE is utilized as a research tool in the field of biotechnology and material science. Its unique properties make it an interesting subject for studying the interactions between macromolecules and their potential applications in various fields.
Used in Drug Delivery Systems:
Similar to gallotannin, POLY-GAMMA-BENZYL L-GLUTAMATE can be employed in the development of novel drug delivery systems. Its chemical properties and solubility in CHCl3 make it a suitable candidate for improving the delivery, bioavailability, and therapeutic outcomes of various drugs.
Used in Material Science:
POLY-GAMMA-BENZYL L-GLUTAMATE's unique structure and properties can be harnessed in the field of material science for the development of new materials with specific characteristics, such as enhanced strength, flexibility, or biodegradability.

Check Digit Verification of cas no

The CAS Registry Mumber 25014-27-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,0,1 and 4 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 25014-27:
(7*2)+(6*5)+(5*0)+(4*1)+(3*4)+(2*2)+(1*7)=71
71 % 10 = 1
So 25014-27-1 is a valid CAS Registry Number.

25014-27-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (P5136)  Poly-γ-benzyl-L-glutamate  mol wt 150,000-350,000

  • 25014-27-1

  • P5136-1G

  • 5,603.13CNY

  • Detail
  • Sigma

  • (P5011)  Poly-γ-benzyl-L-glutamate  mol wt 30,000-70,000

  • 25014-27-1

  • P5011-500MG

  • 2,246.40CNY

  • Detail
  • Sigma

  • (P5011)  Poly-γ-benzyl-L-glutamate  mol wt 30,000-70,000

  • 25014-27-1

  • P5011-1G

  • 3,871.53CNY

  • Detail
  • Sigma

  • (P5386)  Poly-γ-benzyl-L-glutamate  mol wt 70,000-150,000

  • 25014-27-1

  • P5386-1G

  • 5,779.80CNY

  • Detail

25014-27-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name poly(γ-benzyl-L-glutamate) macromolecule

1.2 Other means of identification

Product number -
Other names poly(gamma-benzyl-L-glutamate) macromolecule

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:25014-27-1 SDS

25014-27-1Relevant articles and documents

Design, synthesis, and biological evaluation of desmuramyl dipeptides modified by adamantyl-1,2,3-triazole

?kalamera, Dani,Antica, Mariastefania,Car, ?eljka,Dra?enovi?, Josip,Milkovi?, Lidija,Perokovi?, Vesna Petrovi?,Ribi?, Rosana,Stojkovi?, Ranko,Tomi?, Sr?anka

supporting information, (2021/11/01)

Muramyl dipeptide (MDP) is the smallest peptidoglycan fragment able to trigger the immune response. Structural modification of MDP can lead to the preparation of analogs with improved immunostimulant properties, including desmuramyl peptides (DMPs). The aim of this work was to prepare the desmuramyl peptide (L-Ala-D-Glu)-containing adamantyl-triazole moiety and its mannosylated derivative in order to study their immunomodulatory activities in vivo. The adjuvant activity of the prepared compounds was evaluated in a murine model using ovalbumin as an antigen, and compared to the reference adjuvant ManAdDMP. The results showed that the introduction of the lipophilic adamantyl-triazole moiety at the C-terminus of L-Ala-D-Glu contributes to the immunostimulant activity of DMP, and that mannosylation of DMP modified with adamantyl-triazole causes the amplification of its immunostimulant activity.

Rhamnolipid inspired lipopeptides effective in preventing adhesion and biofilm formation of Candida albicans

Jovanovic, Milos,Radivojevic, Jelena,O'Connor, Kevin,Blagojevic, Stevan,Begovic, Biljana,Lukic, Vera,Nikodinovic-Runic, Jasmina,Savic, Vladimir

supporting information, p. 209 - 217 (2019/03/23)

Rhamnolipids are biodegradable low toxic biosurfactants which exert antimicrobial and anti-biofilm properties. They have attracted much attention recently due to potential applications in areas of bioremediation, therapeutics, cosmetics and agriculture, however, the full potential of these versatile molecules is yet to be explored. Based on the facts that many naturally occurring lipopeptides are potent antimicrobials, our study aimed to explore the potential of replacing rhamnose in rhamnolipids with amino acids thus creating lipopeptides that would mimic or enhance properties of the parent molecule. This would allow not only for more economical and greener production but also, due to the availability of structurally different amino acids, facile manipulation of physico-chemical and biological properties. Our synthetic efforts produced a library of 43 lipopeptides revealing biologically more potent molecules. The structural changes significantly increased, in particular, anti-biofilm properties against Candida albicans, although surface activity of the parent molecule was almost completely abolished. Our findings show that the most active compounds are leucine derivatives of 3-hydroxy acids containing benzylic ester functionality. The SAR study demonstrated a further increase in activity with aliphatic chain elongation. The most promising lipopeptides 15, 23 and 36 at 12.5 μg/mL concentration allowed only 14.3%, 5.1% and 11.2% of biofilm formation, respectively after 24 h. These compounds inhibit biofilm formation by preventing adhesion of C. albicans to abiotic and biotic surfaces.

DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS

-

Paragraph 0077, (2019/04/16)

The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexatnethylenediaanine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10 -9 to 10 -5 M. They also displayed neuroprotective, anti-parkinsonian, anti-stroke, anti-ischemic, anti-depressant and anti-amnestic activities in animal models and were active in experimental models of Alzheimer's disease. These in vivo effects of the claimed compounds are displayed in the dose range of 0.01 to 10 mg/kg when administered intraperitoneally.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 25014-27-1